News Update: Shares of ImmunoGen, Inc. Up After 40% Plunge from Friday
Shares of ImmunoGen, Inc. (NASDAQ:IMGN) were up 10% earlier Monday to $5.66, reports Market Watch. Shares of the company dove 40% last Friday after the accelerated approval of the Roche Holding Ltd.-developed breast cancer treatment, T-DM1, was denied by the US Food and Drug Administration. Roche will now have to wait until mid-2012 to re-apply for approval. SmarTrend currently has ImmunoGen in a Downtrend and is monitoring these developments to alert subscribers to any change of trend. Shares of the pharmaceuticals company continue to trade up 11.05% Monday afternoon at $5.73.
Categories: Breast Cancer Treatment Tags: after, Friday, From, ImmunoGen, Inc., News, plunge, Shares, Update
FDA denies accelerated approval for ImmunoGen, Genentech potential breast cancer treatment
FDA denies accelerated approval for ImmunoGen, Genentech potential breast cancer treatment
WALTHAM, Mass. – Federal regulators have ruled that a potential breast cancer treatment from ImmunoGen failed to meet the standard for accelerated approval, the company said Friday.
Read more on Minneapolis-St. Paul Star Tribune
Categories: Breast Cancer Treatment Tags: Accelerated, Approval, breast, cancer, Denies, Genentech, ImmunoGen, Potential, Treatment